

## The determinants of trust in drug: Relation pharmaceutical-physicians laboratories

<sup>1</sup>Salma Ayeub, <sup>2</sup>Kaouther Saied Ben Rached

*Faculty of Economics and Management of Tunis, University of Tunis El Manar, Research Laboratory: Business and Marketing Research (ERMA),*

---

**ABSTRACT:** The relationship "pharmaceutical physicians-laboratories" is a concept little explored in marketing. This research allows to identify the main antecedents of the institutional trust in the relation pharmaceutical-physicians laboratories. The results of a survey of 220 medical specialists show that the reputation of pharmaceutical laboratories and the experience are a the antecedent of the physicians trust in the drug.

**KEY WORDS:** Relation pharmaceutical-physician laboratories, Trust in drug, Reputation

---

### I. INTRODUCTION

A study, conducted in France, indicates that more than 130,000 hospitalizations directly attributable to drugs occur each year and that the average length of hospitalization is 9 days, which clearly means that the side effects are serious. The survey even goes so far as to point out that the number of deaths in France due to drugs is between 8,000 and 13,000 per year.<sup>1</sup> In recent years, a series of drug-related health crises has accentuated health problems. Such health crises have tarnished the brand image of pharmaceutical laboratories in the eyes of physicians. When prescribing medication, physicians have to take into consideration the risks and side effects of drugs. However, with the pressure of competition and the risk of disappearing from the market, pharmaceutical laboratories race to increase their financial profitability by selling as many of their products as possible (Perez, 2008). Today, "the medication industry suffers from a trust paradox observable between the nobility of the mission to save lives and the suspicion cast on its medication-related operations" (Andreani and al.2014, P. 80). Accordingly, the role of pharmaceutical laboratories has shifted towards restoring trust with healthcare professionals. This amounts to building and strengthening trust of physicians towards drug. To better develop this "laboratory- physician" relationship, this study proposes to model trust between pharmaceutical laboratories and physicians.

The concept of trust has been the subject of several marketing studies and researchers have emphasized its important role in relationship marketing. Indeed, trust is a very broad and ambiguous construct, and it varies depending on research contexts. According to Chouk and Perrien (2005), trust is known as a cornerstone of any exchange relationship. The relationship marketing literature has identified three research streams that examined the concept of relationship (Ricard and Perrien, 1999). The first strand focuses on the nature of relationships and their evolution. This strand consists of studying strategic marketing from a strategic point of view (Perrien, Filiatrault and Ricard, 1993). The second strand highlights the behavioural dimensions bearing on relationships, like customer stress, reciprocal commitment and trust, as these variables play a central role in developing an effective relationship (Doney and Cannon, 1997; Morgan and Hunt, 1994). This research strand focuses on trust in a supplier/seller relationship (Ricard and Perrien, 1999). The third strand explores relationship outcomes, such as customer satisfaction, perceived quality and relationship duration (Paulin and al. 1997). This present study bears on such a relationship perspective and examines the behavioral mechanisms affecting relationships in the pharmaceutical sector. Indeed, previous relationship marketing research has extensively studied industrial marketing. However, a rather limited number of studies has focused on studying trust towards medication. In this regard, this study examines the role of trust in a pharmaceutical laboratory-physician relationship. Specifically, it aims to identify the factors and determinants of trust towards medication.

### II. REVIEW OF THE LITERATURE

In an effort to reconcile the different accounts on the construct of trust, marketing research has identified two types of trust, one interpersonal, and the other institutional (Sirdsmukh and al. 2002; Kennedy and al. 2001 and Doney and Cannon, 1997). Interpersonal trust involves a relationship between two natural individuals, in a

---

<sup>1</sup> www.senat.fr

business context, it informs the state of the relationship between industrial or service buyers and sellers" (Ochi, 2006, P.7). Institutional trust is "the willingness to rely on the reliability and benevolence of a trusted party in a risky situation" (Benamour, 2000). The pharmaceutical laboratory-physician relationship is a relationship between an organization and an individual. Research in this area has named this type of trust as institutional trust (Benamour, 2000; Doney and Canon, 1997). Institutional trust represents a niche of industrial B to B marketing research, yet it remains a concept that is little studied (Gatfaoui, 2003), its application in management research is more recent (Gatfaoui, 2007) and it is approached as a cognitive process. In the 1990s, this concept evolved and was conceived as a conceit in the relationship between companies and customers (Sonnenberg, 1993).

In an industrial context, building trust reports to a process of creating, developing and maintaining a relationship between a customer and an institution (Bories, 2006). Indeed, laboratories that wish to establish a lasting relationship based on knowledge and customer identification (health professionals) do so mainly through honesty and reputation. Trust in medication is a very delicate concept, like the drug itself, and covers a variety of dimensions (Andreani and al. 2010). Dimensions of medication have been defined by pharmaceutical laboratories as a specific consumer product (benefit/risk ratio, dispensed in pharmacies), high-level research, mandatory information (mandatory packaging, information for professionals, etc.), an industry subject to strict regulations and rules, and companies that integrate societal concerns (environment, public health, etc.). Bearing on these attributes, and on a review of the literature on consumer behavior, trust in drug has five dimensions: drug reliability, investment, information transparency, social responsibility and medical supplier credibility. Accordingly, this study proposes to measure general trust in medication within a pharmaceutical laboratory-physician relationship.

The first empirical study on the factors of institutional trust was developed by Doney and Cannon, (1997). According to their results, reputation, size, opportunistic behavior, information sharing and duration of the relationship contribute to institutional trust. For company size and opportunistic behavior, these two variables will not be taken into consideration in our study. This study is a qualitative exploratory study designed using a set of semi-structured interviews conducted with a sample of 14 physicians. The aim to determine the factors explaining development of trust in a medical environment. The results of this study allowed us to identify laboratory reputation and professional experience as factors explaining physicians trust in a drug (Ayebe and Ben Rached, 2017).

**Corporate reputation :** Supplier reputation is defined as the extent to which companies and people in the industry believe that the supplier is honest and concerned about its customers (Doney and Cannon, 1997). Firm reputation, as experienced by its stakeholders, is critical as it reduces transaction costs, and positively influences the firm's bottom line (Shapiro, 1983) and it directly bears on customer variables such as consumer trust and loyalty (Walsh et al. 2006; Roberts and Dowling, 2002; Rose and Thomsen, 2004). Loyalty is presented as an important factor in the success of businesses (Walsh and Beatty, 2007). It infuses trust in investors, which is why managers rally to ensure that reputation is consistent over time (Nguyen and Leblanc, 2001). Under this perspective, reputation is an important dimension influencing trust formation. The relationship between reputation and trust has been the subject of several marketing studies. Indeed, several authors (Caruana et al. 2004; Nguyen and al. 2008; Walsh and Beatty 2007; Gardberg and Fombrun, 2002; Fombrun and Rindova 2000) have emphasized the importance of this relationship in industrial marketing claiming that it is the most significant variable (Akrouit and Akrouit 2011).

Previous research (Gardberg and Fombrun 2002; Gotsi and Wilson 2001) has suggested that firms with a positive reputation have a competitive advantage and are likely to attract more customers.

Bearing on the above proposals, the following hypothesis is formulated:

H1-Pharmaceutical laboratories reputation has a positive impact on physicians trust in a drug

H1-1. Reputation has a positive impact on drug reliability

H1-2. Reputation has a positive impact on investment in innovation

H1-3. Reputation has a positive impact on information transparency

H1-4. Reputation has a positive impact on medical suppliers credibility

H1-5. Reputation has a positive impact on corporate social responsibility

**Experience :** Vincens (2001) distinguished three dimensions in the notion of experience. "The first dimension relates to the individual. The second highlights collective workers, i.e. collective knowledge, human capital, which can take the form of a work yard, a company or a factory. The third dimension focuses on collective bargaining and uses the notion of professional experience as a basis for collective recognition of a right to seniority.

This study subscribes itself to the first dimension. Accordingly, we assume that an experienced person is the one who can claim competences to their practice of a professional activity. According to Gharbi (1998, p.21), experience "represents the history of practical interactions between the individual and the product or activity and the information attached to it". It allows customers to assess quality of a product and/or a service (Gatfaoui, 2005). The concept of work experience has been addressed in several areas of consumer behavior such as information quality, trust formation and development, satisfaction and decision making. However, empirically, this concept has not been studied in the context of other consumer and marketing concepts such as choice, attitudes, consumer satisfaction, or brand equity (Schmitt, 2010). The marketing literature has found that trust develops and increases over time (Donney and Canon, 1997). Indeed, trust is likely to be affected by experience and interaction with an individual (Gulati and Sytch, 2008). Furthermore, personal experience will, in each case, change perceptions, attitudes, and intentions of the end customers in a significant way (Salo and Karyaluoto, 2007). While assessing some factors explaining trust, previous experience is signaled out (Gulati and Sytch, 2008). Then, recognition of the endogenous nature of institutional trust has led some researchers to postulate that direct experience is, at times, necessary to assess and ensure a partner's willingness to engage in a trustworthy behavior (Arrow, 1974; Sako, 1991). Gulati and Sytch,(2008) found that previous experience is likely to affect the measurement of trust between firms. The knowledge-based concept of trust develops over time through experience and interaction with a partner. (Ben Naoui, 2014)


In the medical field, trust in medication does not only bear on product quality, but also on knowledge and experience. The literature highlighted the importance of experience in explaining and developing trust. Therefore, our second hypothesis is formulated:

H2-Experience has a positive impact on physicians trust in a drug

- H2-1. Experience has a positive impact on reliability
- H2-2. Experience has a positive impact on investment in innovation
- H2-3. Experience has a positive impact on information transparency
- H2-4. Experience has a positive impact on supplier credibility
- H2-5. Experience has a positive impact on corporate social responsibility

The conceptual model of the study (Figure 1) is constructed to study and determine the causal relationship between the reputation of pharmaceutical laboratories, experience and physicians trust in a drug.

Fig. 1. Conceptual model



## II. RESEARCH METHODOLOGY

In this section, we present the research methodology used to operationalize the studied variables and to validate the different measurement instruments.

**The sampling method :** This study examines a set of data collected face-to-face from a convenience sample consisting of 220 Tunisian physicians. The sample consists of (46.4%) males and (53.6%) females; 59% of them operate in the private sector; and 41% in the public sector. Our variables were measured using multi-item measurement scales known for their validity and reliability (Peter, 1979). To measure the construct of trust in medication, we adopted Andreani and al. (2014) five-dimension scale: trustworthiness, investment in innovation, information transparency, supplier credibility, and social responsibility. Each dimension consists of 6 items, except "information transparency" which has 9 items. Each item is evaluated by a six-point Likert-type scale (1: strongly agree; 6: strongly disagree). To measure reputation of pharmaceutical laboratories, we used the Doney and Cannon (1997) scale. This scale includes 3 items, the third of which is inverted, and is measured by a 7-point Likert scale ranging from 1 "strongly agree" to 7 "strongly disagree". To measure professional experience in terms of physicians seniority in the medical field, we used the interval scale of Nilson et al. (2013). As a follow-up step, we tested the psychometric quality of our measurement scales. The final drug trust measurement scale included 33 items. After several purification analyses, it was reduced to 20 items. The items that were eliminated have a relatively low psychometric quality. After purifying our measurement scales, we proceeded to a confirmatory analysis in order to study our latent variables. We used the structural equation method, which allows for introducing several variables to be explained in the same analysis and for studying the causal relationships between the independent and the dependent variables (Roussel and al. 2002). In addition, we estimated the parameters of our model using the Partial Least Square (PLS) method. The choice of this method suits our sample size of 220 physicians.

## III. RESULTS

The confirmatory analysis allowed us to test the validity of the hypothesized relationships (Roussel and al. 2002). Indeed, factor loadings of the items vary between 0.6122 and 0.9670, an exception is the information transparency item, INF2: "information available on the package of a drug is clear and understandable". Then, eliminating this item would improve convergent validity (Fornell and Larcker, 1981). However, a second PLS-based CFA allowed us to conclude that factor loadings of the items are satisfactory and good (between 0.68 and 0.98). According to Evard et al. (2003), internal validity (reliability of the scales) is respected if it meets the following conditions: CR reliability and Cronbach's should be greater than 0.7 (Chin, 2000;1998). The results of these estimates affirm that these conditions are met.

Moreover, Fornell and Larcker (1981) indicate that for a measurement model to be valid, its convergent and discriminant validity should also be checked. Convergent validity coefficients of our model are satisfactory extracted mean variance (EVA) > 0.5 (Table 1), and discriminant validity conditions are met (AVE of each variable is greater than the square correlation of all other latent variables) (Table 2). Therefore, we can conclude that our measurement model is valid.

**Table 1.** The convergent validity of constructs

Constructs	AVE	CR	Alpha Cronbach
Reputation	0,664	0,8920	0,8634
Experience	1,000	1,000	1,000
Reliability	0,6433	0,8973	0,8923
Investment in innovation	0,6884	0,9432	0,8674
Information transparency	0,6970	0,9122	0,7822
Suppliers credibility	0,6656	0,8962	0,8469
Corporate social responsibility	0,7922	0,8989	0,8671

**Table 2.** The discriminant validity.

<b>Constructs</b>	Corporate social responsibility	Suppliers credibility	Experience	Reliability	Information	innovation	Reputation
Corporate social responsibility	<b>0,890</b>						
Suppliers credibility	0,0503	<b>0,815</b>					
Experience	0,1759	0,3376	<b>1,0000</b>				
Reliability	0,2683	0,1121	0,1200	<b>0,8020</b>			
Information	0,0671	0,3921	0,0685	0,0383	<b>0,834</b>		
innovation	0,1635	0,0231	0,2562	0,0952	0,1486	<b>0,8296</b>	
Reputation	0,2803	0,0988	0,0492	0,1342	0,1344	0,1874	<b>0,8148</b>

The results of the structural model analysis show that explained variance as well as predictive validity are satisfactory. However, our model has a GOF= 0.46 which is higher than 0.36, indicating that our model fit is good (Tenenhaus et al. 2004 and Wetzels et al, 2009).

**Table 3.** The result of the hypothesis test

<b>Hypothèse</b>	<b>B</b>	<b>T valeur</b>	<b>Acceptation/Rejet</b>
expérience -> RSE	0,1645	2,2224**	Acceptée
expérience-> crédibilité	0,4385	3,6422**	Acceptée
expérience -> fiabilité	0,1589	1,9456*	Acceptée
expérience -> information	0,0731	0,8083	Rejetée
expérience -> innova	0,2771	2,934**	Acceptée
reputation -> RSE	0,2824	3,618**	Acceptée
reputation -> crédibilité	0,8479	1,7822*	Acceptée
reputation-> fiabilité	0,1809	1,9451*	Acceptée
reputation-> information	0,1491	1,833*	Acceptée
reputation -> innovation	0,3239	1,8922*	Acceptée

\*Seuil de 10% ; \*\* Seuil de 5%

#### IV. DISCUSSION OF THE RESULTS

The results of our study allowed us to conclude that reputation of pharmaceutical laboratories perceived by physicians exerts a positive and significant effect on physicians trust in a drug. This finding provides a better understanding of how different dimensions of drug trust can be influenced by reputation of pharmaceutical laboratories. In this study, reputation of pharmaceutical laboratories can affect physicians trust in a drug. Today, pharmaceutical laboratories should seek to build up the pharmaceutical laboratory- physician relationship through their reputation (honesty). Faced with a very tough competition and to be able to meet patient needs, pharmaceutical laboratories should integrate the concept of trust into their corporate strategies in order to reassure and retain physicians to prescribe their medication. In addition, the results on the causal relationship between work experience and trust in a drug indicate that there is a partially positive relationship. Several studies have shown that experience has a positive effect on trust. For example, Doney and Cannon (1997) and Gulati and Sytch (2008) highlighted that a relationship between two parties takes time. Trust development often depends on a direct experience with the company and its suppliers (Donney and Cannon, 1997). On the other hand, hypothesis H2.3, assuming that experience does not have a significant impact on



information transparency, was rejected. Such a finding can be explained by the fact that initial trust is based on information (McKnight et al. 1998). Moreover, given that our sample consists of physicians who are experts and competent in the medical field, as a result, physician trust is still in its developmental and maintenance stages. Therefore, the rejection of this hypothesis replicates the conclusions of (McKnight et al. 1998; Chouk and Perrien, 2005). The results also contributed in identifying and empirically modeling the relationship between pharmaceutical laboratories and physicians. Two contributions are highlighted. The first is managerial and bears on the evolution of the pharmaceutical sector and more specifically on a context of a health crisis. The second is theoretical, which is modeling the concept of trust which is not well defined in the field of health marketing. From a management point of view, this study identified the levers on which pharmaceutical laboratories should act in order to develop a sustainable trust-based relationship with physicians. As a recommendation, pharmaceutical laboratories are called upon to optimize the benefits of managing their relationship with physicians. Indeed, pharmaceutical laboratories need to leverage efforts to convince physicians to prescribe their medication. It is therefore strongly recommended to reassure them and to create a climate of trust for them. Customer trust can also increase significantly when the company is perceived as having a good reputation (Doney and Cannon 1997; Jarvenpaa and al. 2000). Laboratories should communicate well with their physicians on the attributes of their products and the company, namely: drug reliability, information transparency and clarity, investment, supplier credibility and social responsibility. This study showed the benefits of exchange within a sustainable relationship between pharmaceutical laboratories and physicians. The results allowed us to highlight the role of reputation of pharmaceutical laboratories, which has a positive effect on physician trust in a drug. Nevertheless, the study has some sample-related limitations. It would be interesting to conduct a study on a specific medical specialty with a specific company profile.

#### REFERENCES

1. Akrou, H. and Akrou, W. (2011) : « La confiance en B To B : Vers une approche dynamique et intégrative » Recherche et Applications Marketing, Vol 26,1 ; pg.59-81
2. Andreani, J.C., Moulins, J.L., Conchon, F., Bascoul, G., Benjamin, B., Dubec, J. (2010) : « La confiance dans le médicament : proposition d'une échelle de mesure » Actes de la 1ère Journée Internationale du Marketing Santé, Lille.
3. Andreani, J.C., Moulins, J.L., Conchon, F., Fons, C., Boeuf, B. (2014) : « Une approche protéiforme de la confiance du consommateur. Le cas des médicaments » Décision Marketing, N° 75, pg.79-94.
4. Ayeb, S. and Ben Rached Saied, K. (2017): « Les facteurs expliquant la confiance dans le médicament et leurs influences sur la prise de décision médicale: Une étude exploratoire » 15ème colloque de l'Association Tunisienne de Marketing.
5. Benamour, Y. (2000) : « Confiance interpersonnelle et confiance institutionnelle dans la relation client-entreprise de service : une application au secteur bancaire français, Thèse de doctorat, Université Paris IX Dauphine.
6. Caruana, A., Ramasashan, B., and Krentler, K. A. (2004): "Corporate reputation, customer satisfaction, et customer loyalty: What is the relationship?" In H. E. Spotts (Ed.), Proceedings: Developments in marketing science, vol. 27 (p. 301). Coral Gables, FL: Academy of Marketing Science.
7. Chin, W. (2000): "Partial Least Square for researchers: a overview and presentation of recent advances using the PLS approach", <http://discnt.cba.uh.edu/chin/indx.html> , 2000
8. Chin, W. (1998) : "The partial least squares approach for structural equation modeling. In: Marcoulides, G.A. (Ed.), Modern Methods for Business Research". Lawrence Erlbaum Associates, London, pg. 295–336.
9. Chouk, I. and Perrien, J. (2005) : « La confiance du consommateur vis-à-vis d'un marchand Internet : Proposition d'une échelle de mesure », Revue Française du Marketing, 205, pg. 5-20.
10. Doney, P.M. and Cannon, J.P. (1997): "An examination of the nature of trust in buyer-seller relationships", Journal of Marketing, 61, 2, pg.35-51.
11. Evrard, Y., Pras B. and Roux E. (2003) : « Market Etudes et recherches en Marketing », 3ème Edition, DUNOD, PARIS.
12. Fombrun, C. J., and Rindova, V. (2000): "The road to transparency: Reputation management at royal dutch/shell. In M. Schultz, M. J.Hatch, & M. H. Larsen (Eds.), The expressive organization (pg. 77–96). Oxford: Oxford University Press
13. Fornell, C. and Larcker, D. F. (1981): " Evaluating Structural Equation Models with Unobservable Variables and Measurement Error. Journal of Marketing Research, 18(3), 39-50.

14. Gardberg, N. and Fombrun, C. (2002) : « The global reputation quotient project : First steps Towards a cross-Nationally valid Measure of corporate reputation » *Corporate reputation Review*, 4 (4), pg.303-307.
15. Gatfaoui, S. (2003) : « Les mécanismes de la confiance dans le discours des clients : le cas d'une banque mutualiste », Actes du 19<sup>e</sup> Congrès de l'AFM, vol 19, Cd-rom, Tunis
16. Gatfaoui, S. (2007) : « Comment développer une relation bancaire fondée sur la confiance » *Décisions Marketing*, Vol, 46, 91-103
17. Gatfaoui, S. (2005) : « Une analyse dynamique de la construction de la confiance dans la relation client-particulier/banque : une approche par les études de cas rétrospectives » Thèse de Doctorat en Sciences de gestion.
18. Gharbi, J.E. (1998) : « Les facteurs qui influencent les processus décisionnels des consommateurs lors d'un achat par Internet », Thèse présentée à la Faculté des études Supérieures en vue de l'obtention du grade de Philosophie et Administration,.
19. Gotsi, M. and Wilson, A.M. (2001): "Corporate reputation: seeking a definition", *Corporate Communications: An International Journal*, Vol.6 Iss 1 pg. 24 –
20. Gulati, R. and Sytch, M. (2008): "Does familiarity breed trust? Revisiting the antecedents of trust." *Managerial and Decision Economics*, 29(2-3): pg. 165-190.
21. Jarvenpaa, S.L., Tractinsky, N. and Vitale, M. (2000) : « Consumer trust in an Internet Store: A crosscultural validation ». *Journal of Computer Mediated Communication*, vol. 5, no 2, pg. 1-35.
22. McKnight, D.H., Cummings, L.L. and Chervany, N.L. (1998): 'Initial trust formation in new organizational relationships', *Academy of Management Review*, 23, 1–18.
23. McKnight, H. D., Choudhury, V. and Kacmar C. (2002): "Developing and Validating Trust Measures for E-Commerce: An Integrative Typology", *Information Systems Research*, 13 (3), pg. 334 –359
24. Morgan, R. and Hunt, S. (1994): "the commitment-trust theory of relationship marketing" *Journal of Marketing*, 58, 3, p. 20.
25. Nguyen, N. and Leblanc, G. (2001): « Corporate image and corporate reputation in customers' retention decisions in services », *Journal of Retailing and Consumer Services*, N° 8, pg. 227-236
26. Nguyen, N., LeBlanc, G. and Leclerc, A. (2008) : « Les effets de la compétence et de la bienveillance du personnel de contact sur la perception de la réputation d'entreprise : une étude dans les services financiers », ASAC, Halifax, Nouvelle-Écosse.
27. Roberts, P. W. and Dowling, G. R. (2002): "Corporate reputation and sustained superior financial performance". *Strategic Management Journal*, 23(12), pg.1077–1093.
28. Rooks, G., Raub, W., Selten, R. and Tazelaar, F. (2000): "How inter-firm co-operation depends on social embeddedness: a vignette study" . *Acta Sociologica* 43: 123–137.
29. Rose, C. and Thomsen, S. (2004): "The impact of corporate reputation on performance: Some Danish evidence". *European Management Journal*, 22(2), pg. 201–210.
30. Roussel, P., Durrieu, F., Campoy, E. and El Akrami A. (2002) : « Méthodes d'équations structurelles : Recherche et applications en gestion ». Paris, Economica.
31. Salo, J. and Karjaluoto, H. (2007): « A conceptual model of trust in the online environment », *Online Information Review*, Vol. 31, No. 5, pg. 604-621.
32. Shapiro, C. (1983): "Premiums for high-quality products as returns to reputations", *The quarterly Journal of Economics*, Vol, 98, pg.659-681.
33. Vincens, J. (2001): « Définir l'expérience professionnelle » *Travail et Emploi* n°85.
34. Walsh, G. and Beatty, S. (2007) : « Customer-based corporate reputation of a service firm : scale development and validation" *Journal of Academy of Marketing Science*, n°35, pg. 127-143.
35. Walsh, G., Dinnie, K. and Wiedmann, K.P. (2006): "How do corporate reputation and customer satisfaction impact customer defection? A study of private energy customers in Germany". *Journal of Services Marketing*, 20(6):pg.412 – 420.